John Greisch - Actelion Director

Director

Mr. John J. Greisch was Member of the Board of Directors at Actelion Ltd since April 18, 2013. He is Chairman of the Compensation Committee and Member of the Nominating and Governance Committee at the Company. He is currently President and Chief Executive Officer of HillRom Holdings, Inc. Before joining HillRom, Mr. Greisch spent seven years at Baxter International, Inc. in various executive positions in corporate finance, operations and general management. From 20042006, he served as Chief Financial Officer and from 20062009 as President International Operations. Mr. Greisch earned a Bachelors degree in Business Administration from the Miami University and Masters degree in Management from the Northwestern University in Illinois. Mr. Greisch also serves on the Board of Lurie Childrens Hospital in Chicago and is a past member of the Business School Advisory Board for Miami Universitys Farmer School of Business. since 2013.
Age 61
Tenure 11 years
Professional MarksMBA
Phone41 61 565 65 65
Webhttp://www.actelion.com

Actelion Management Efficiency

The company has return on total asset (ROA) of 23.87 % which means that it generated a profit of $23.87 on every $100 spent on assets. This is very large. Similarly, it shows a return on equity (ROE) of 47.08 %, meaning that it generated $47.08 on every $100 dollars invested by stockholders. Actelion's management efficiency ratios could be used to measure how well Actelion manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

James ChampyAnalog Devices
75
John DonofrioFARO Technologies
56
John HodgsonAnalog Devices
71
Stephen ColeFARO Technologies
66
Lynn BrubakerFARO Technologies
60
Katherine SavittAlaska Air Group
51
Carlos CollGrupo Aeroportuario Del
56
Bruce EvansAnalog Devices
58
Daniel HanrahanCedar Fair LP
62
Ben StocksPorvair Plc
61
Edward FrankAnalog Devices
61
Marvin SamburFARO Technologies
70
Debra SmithartOglesbyCedar Fair LP
65
Kenton SicchitanoAnalog Devices
73
Ian SainesAir Lease
58
Robert MiltonAir Lease
60
Susan LiAlaska Air Group
35
Dhiren FonsecaAlaska Air Group
56
Rasmus ChristiansenGrupo Aeroportuario Del
68
John CaldwellFARO Technologies
68
Kenneth ThompsonAlaska Air Group
63
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. Actelion [ALIOF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Actelion Leadership Team

Elected by the shareholders, the Actelion's board of directors comprises two types of representatives: Actelion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actelion. The board's role is to monitor Actelion's management team and ensure that shareholders' interests are well served. Actelion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actelion's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Widman, Co-Founder
Christian Albrich, Member of the Management Board, Senior Vice President Head Global Human Resources
Walter Fischli, Senior Vice President Academia Relations
Robert Bertolini, Member of the Board of Directors
Carl Feldbaum, Member of the Board of Directors
Andre Muller, Member of the Management Board, CFO, Executive Vice President
John Greisch, Director
Rudi Frank, Senior Vice President Head Global Quality Management, Member of the Extended Executive Committee
Marian Borovsky, Sr. VP, Group General Counsel and Corporate Secretary
Werner Henrich, Member of the Board of Directors
Nicholas Franco, Member of the Management Board, Executive Vice President Chief Business Development Officer
Martine Clozel, Founder, Chief Scientific Officer, Head of Drug Discovery Pharmacology and Preclinical Devel. and Sr. VP
Juhani Anttila, Member of the Board of Directors
JeanPierre Garnier, Chairman of the Board of Directors
David Stout, Member of the Board of Directors
JeanPaul Clozel, CEO, Member of the Executive Committee, Delegate to the Board of Directors
Guy Braunstein, Member of the Management Board, Executive Vice President Head of Clinical Development
Andrew Weiss, Head of Investor Relations and Corporate Communications and Sr. VP
Herna Verhagen, Member of the Board of Directors
Michael Jacobi, Member of the Board of Directors
Jean Malo, Member of the Board of Directors
Otto Schwarz, COO and Executive VP
Roland Haefeli, Member of the Management Board, Senior Vice President Head of Investor Relations & Public Affairs
Thomas Weller, Vice President Co-Head of Drug Discovery
Peter Gruss, Member of the Board of Directors

Actelion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Actelion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Actelion in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Actelion's short interest history, or implied volatility extrapolated from Actelion options trading.

Pair Trading with Actelion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actelion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actelion will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Xcel Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xcel Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xcel Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xcel Energy to buy it.
The correlation of Xcel Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xcel Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xcel Energy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xcel Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Actelion OTC Stock

If you are still planning to invest in Actelion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Actelion's history and understand the potential risks before investing.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital